



Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference

March 7, 2019

BEDFORD, Mass., March 7, 2019 – Stoke Therapeutics will present next week at the Cowen and Company 39th Annual Health Care Conference in Boston on its work to develop the first gene-specific, disease-modifying therapies for treatment of Dravet syndrome and other severe genetic diseases.

Huw M. Nash, Ph.D., Stoke's chief operating officer and chief business officer, will present on Stoke's novel antisense oligonucleotide (ASO) medicines, which target pre-mRNA splicing to increase protein expression to near normal levels. Stoke's ASOs utilize the Company's proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, and are designed to increase the expression of protein by individual genes in a patient.

Stoke is working to advance its lead product candidate for treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome affects approximately 35,000 patients across the U.S., Canada, Japan, Germany, France and the United Kingdom and is primarily caused by loss-of-function mutations in the SCN1A gene which encodes the Nav1.1 protein. Dr. Nash will present preclinical data showing the impact of Stoke's TANGO technology on Nav1.1 protein expression in mouse models.

Stoke is also developing ASO therapies for other genetic epilepsies, as well as genetic diseases of the central nervous system, eye, liver and kidney.

Stoke's presentation details:

Date: Monday, March 11, 2019

Time: 8:00 – 8:25 a.m. EST

Location: Boston Marriott Copley Place, MIT Conference Room, 3rd Floor

About Stoke Therapeutics

Stoke Therapeutics is a biotechnology company working to increase gene expression to treat a wide array of severe genetic diseases, including genetic conditions affecting the central nervous system, eye and liver. Stoke was launched in 2018 with a \$40 million Series A investment funded by Apple Tree Partners. For more information visit www.stoketherapeutics.com and follow Stoke on Twitter [@StokeTx](https://twitter.com/StokeTx).

Media Contact

Sara Green

Ten Bridge Communications

sgreen@tenbridgecommunications.com

617-233-1714